Therefore, we speculate that CIB1 affects lenvatinib resistance in HCC by affecting certain pathways.38 Previous studies have shown that lenvatinib gradually fails to fully inhibit MAPK signaling during administration, which limits the drug response.25 Thus, MAPK pathway activation demonstrates the adverse consequences of lenvatinib therapy. The gene discussed is CIB1; the disease is hepatocellular carcinoma.